Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04373720

MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas

This trial uses magnetic resonance elastography (MRE) to estimate tissue stiffness (hardness or softness of the tissue) in tissue that is affected by radiation treatment (radiation necrosis) and tumor tissue that has come back (recurrent) after treatment in patients with gliomas. Diagnostic procedures, such as MRE, may estimate the differences in tissue stiffness between radiation necrosis and recurrent glioma post treatment and ultimately lead to a more accurate diagnosis and/or surgery, and/or a better assessment of the disease's response to treatment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

M D Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

Location contact

MD

CONTACT

Melissa Chen

PRINCIPAL_INVESTIGATOR

Melissa Chen, MD

CONTACT

713-745-9789

About this study

PRIMARY OBJECTIVES:

I. To estimate the mean lesion stiffness in patients with radiation necrosis using magnetic resonance elastography (MRE).

II. To estimate the mean lesion stiffness in patients with glioma recurrence using magnetic resonance elastography (MRE).

SECONDARY OBJECTIVE:

I. To investigate the mean lesion stiffness between radiation necrosis and glioma recurrence.

OUTLINE:

Patients undergo MRE over 10 minutes and then undergo standard of care magnetic resonance imaging (MRI) of the brain with and without contrast at baseline. Within 4 weeks after the initial MRI and MRE scans, patients may undergo standard of care biopsy to check the status of the disease. Within 48 hours after biopsy, patients undergo standard of care MRI to check the status of the disease. Patients who do not undergo biopsy undergo standard of care MRI 4-8 weeks after MRE scan to check the status of the disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >/=18 years old.
  • History of a pathology proven intracranial glioma (including IDH mutant, IDH wildtype or 1p19q co-deleted tumors) treated with chemotherapy and radiation.
  • The lesion of concern (T2 Flair Hyperintense or contrast enhancing lesion) is > 2 cm
  • Patient is able to understand and give consent to participation in the study.

Exclusion criteria

  • Patients less than 18 years of age.
  • Pregnant.
  • Known allergy to gadolinium-based contrast agents.
  • Renal failure as evidenced by a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m2.
  • Pacemakers, electronic stimulation, metallic foreign bodies and devices and/or other conditions that are not MR safe, which include but are not limited to:
  • electronically, magnetically, and mechanically activated implants
  • ferromagnetic or electronically operated active devices like automatic cardioverter defibrillators and cardiac pacemakers
  • metallic splinters in the eye
  • ferromagnetic hemostatic clips in the central nervous system (CNS) or body
  • cochlear implants
  • other pacemakers, e.g., for the carotid sinus
  • insulin pumps and nerve stimulators
  • non-MR safe lead wires
  • prosthetic heart valves (if dehiscence is suspected)
  • non-ferromagnetic stapedial implants
  • claustrophobia that does not readily respond to oral medication

Treatment and study plan

Magnetic Resonance Elastography

Procedure

Undergo MRE

Other names: MRE

Magnetic Resonance Imaging

Procedure

Undergo standard of care MRI

Other names: Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging

Primary outcomes

  1. Mean lesion stiffness

    Time frame: At baseline

    For each patient, a lesion region of interest (ROI) will be created along with its normal appearing contralateral white matter. The stiffness of the tumor ROI and the contralateral white matter ROI will be measured, and the ratios of the stiffness between the two will be calculated. Interval estimates will be computed for mean stiffness ratio in patients with radiation necrosis or glioma recurrence, separately using a 2-sided 95% confidence interval. Outcome variable of stiffness will be assessed between tumor and contralateral white matter with paired t-tests or Wilcoxon signed-rank tests. The Wilcoxon rank-sum test or t-tests will be used to assess the associations between the outcome variable of stiffness ratio and tumor status (recurrence/necrosis).

Study contacts

Contact information is provided by the study sponsor or research team.

Melissa Chen, MD

CONTACT

[email protected]

713-745-9789

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Pilot Study to Assess Mean Lesion Stiffness of Radiation Necrosis and Recurrent Glioma Using Magnetic Resonance Elastography (MRE) in Patients With Previously Treated Gliomas

Important dates

Study start
2020
Primary completion
2028
Study completion
2028
First posted
May 4, 2020
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.